Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in May:

• Truist Securities Life Sciences Summit
  Fireside Chat: Wednesday, May 5 at 12:10 p.m. ET
  Live and archived webcast: available at http://ir.iovance.com/investor-calendar

• Inaugural Multi-Functional Cell Therapies Summit
  Presentation: Leveraging TILs to Engage Solid Tumors as a Natural Multi-Targeted Approach
  Date/Time: Thursday, May 6 at 12:00 p.m. ET
  More information: https://multi-functional-cell-therapies.com/

• 17^th Annual PEGS Boston Virtual Conference & Expo
  Presentation: Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer
  Date/Time: Thursday, May 13 at 2:20 p.m. ET
  More information: https://www.pegsummit.com/

• Sachs Associates 7^th Annual Immuno-Oncology Innovation Forum
  Keynote Presentation: Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors
  Date/Time: Wednesday, May 19 at 12:30 p.m. ET
  More information: https://www.sachsforum.com/7ioif-about.html

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.